Jasper Therapeutics, Inc. has announced a significant corporate action: a 1-for-30 reverse stock split of its common shares, effective November 6, 2026. This decision, aimed at increasing the stock price, follows approval from the company’s shareholders during a special meeting on September 30, 2026.

The reverse stock split is designed to consolidate the number of shares outstanding, which will decrease from approximately 33.3 million to about 1.1 million shares. This move is intended to enhance the marketability of the company’s stock and potentially attract institutional investors who may prefer stocks with higher per-share prices.

Jasper Therapeutics operates within the biological products sector, specifically focusing on products that do not include diagnostic substances. The company is listed on the Nasdaq under the ticker symbol JSPR and is categorized as an emerging growth company.

Background

Founded as Amplitude Healthcare Acquisition Corp, Jasper Therapeutics, Inc. transitioned to its current name and focus on biopharmaceuticals. The company is incorporated in Delaware and has its headquarters in Redwood City, California. The recent filings indicate a proactive approach toward enhancing shareholder value and positioning itself competitively in the biological products market.

What the Filing Says

According to the recent SEC filing dated November 4, 2026, the company stated, “On November 2, 2026, Jasper Therapeutics, Inc. filed a Certificate of Third Amendment to its Second Amended and Restated Certificate of Incorporation... to effect a 1-for-30 reverse stock split.” This amendment was approved by shareholders and is aimed at improving the stock's appeal.

Impact

The reverse stock split will affect all shareholders uniformly, with no changes to their proportional ownership interests, aside from minor adjustments due to fractional shares. Holders of common stock will receive cash for any fractional shares resulting from the split, calculated based on the closing price of the stock on the day prior to the effective date.

This move may influence investor sentiment and trading activity, as the company aims to stabilize its stock price and improve its visibility in the market. Other companies in the biological products industry may observe this strategy as they consider their own capital structures.

What's Next

The filing does not specify further actions following the reverse stock split. However, Jasper Therapeutics is expected to continue its efforts in enhancing its product offerings and market presence.